Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous apomorphine pump for cognitive and psychiatric fluctuations in Parkinson's disease
2008-006045-10Phase 3Completed
- Sponsor
- CHU Rennes
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of apomorphine in Parkinson's disease (PD), sponsored by CHU Rennes. Primary endpoint: Composite efficacy on cognitive and psychiatric fluctuations. Started Mar 2009; status: completed.
02
Drugs
apomorphine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2008-006045-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006045-10.